Depressive Disorder, Major study: Seltorexant
Official title A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
ClinicalTrials.gov ID: NCT07573176
What this study is testing
What is Seltorexant?
This is an investigational oral tablet being studied to see if it can help improve symptoms of major depressive disorder.
Also referred to as JNJ-42847922.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study will see if seltorexant helps reduce depression symptoms compared with a placebo. It will also check the drug’s safety over a longer period.
- Who it's for
- Adults and older adults who have major depressive disorder.
- What's involved
- Participants will receive either seltorexant or a placebo in a double‑blind phase, then all will receive seltorexant in an open‑label phase. They will have regular visits and tests to monitor symptoms and safety.
- Time commitment
- The study lasts several months, with multiple clinic visits for medication, symptom checks, and safety monitoring.
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 74
You may be able to join if
- Meet diagnostic and statistical manual of mental disorders-5th edition (DSM-5) diagnostic criteria for major depressive disorder (MDD), without...
- Experienced at least one MDD episode prior to their current episode based on clinician-confirmed MDD diagnosis/MDE and documented in source records
- Current episode of MDD must be a minimum of 8 weeks in duration and maximum of 24 months duration
- Can be presenting for a new episode of MDD with no adequate antidepressant treatment started in the current episode
- Have taken up to two antidepressant treatments started in the current episode that were stopped (withdrawn), or will be withdrawn (washed out) due to...
You likely can't join if
- Use of ketamine/esketamine in the current depressive episode (up to 2 doses are allowed prior to screening)
- Has treatment-resistant depression (TRD)
- Has a primary DSM-5 diagnosis of panic disorder, generalized anxiety disorder, social anxiety disorder, or specific phobia which has been the primary...
- Current active DSM-5 diagnosis of obsessive-compulsive disorder, posttraumatic stress disorder, anorexia nervosa, bulimia nervosa, or fibromyalgia
- Has a history or current diagnosis of a psychotic disorder, bipolar disorder, autism spectrum disorder, borderline personality disorder, or...
- Has dementia, any dementing disease, intellectual disability, or neurocognitive disorder
See the full eligibility criteria
- Meet diagnostic and statistical manual of mental disorders-5th edition (DSM-5) diagnostic criteria for major depressive disorder (MDD), without psychotic features based upon clinical assessment and confirmed by the...
- Experienced at least one MDD episode prior to their current episode based on clinician-confirmed MDD diagnosis/MDE and documented in source records
- Current episode of MDD must be a minimum of 8 weeks in duration and maximum of 24 months duration
- Can be presenting for a new episode of MDD with no adequate antidepressant treatment started in the current episode
- Have taken up to two antidepressant treatments started in the current episode that were stopped (withdrawn), or will be withdrawn (washed out) due to inadequate response as defined by the Massachusetts general hospital...
- Body Mass Index (BMI) between 18 and 40 kilograms per square meter (kg/m\^2)
- Must be medically stable on the basis of the following performed at screening and blinded (DB) baseline: physical examination (including a brief neurological examination), vital signs (including blood pressure), and...
- Use of ketamine/esketamine in the current depressive episode (up to 2 doses are allowed prior to screening)
- Has treatment-resistant depression (TRD)
- Has a primary DSM-5 diagnosis of panic disorder, generalized anxiety disorder, social anxiety disorder, or specific phobia which has been the primary focus of psychiatric treatment within the past 2 years
- Current active DSM-5 diagnosis of obsessive-compulsive disorder, posttraumatic stress disorder, anorexia nervosa, bulimia nervosa, or fibromyalgia
- Has a history or current diagnosis of a psychotic disorder, bipolar disorder, autism spectrum disorder, borderline personality disorder, or somatoform disorders
- Has dementia, any dementing disease, intellectual disability, or neurocognitive disorder
- Has a current or recent history of homicidal ideation or serious suicidal ideation within the past 3 months or a history of suicidal behavior within the past 6 months
- Has a history of moderate-to-severe substance use disorder including alcohol use disorder according to DSM-5 criteria within 6 months
- Has any significant sleep disorder, including but not limited to untreated/uncontrolled conditions
- Has known allergies, hypersensitivity, intolerance, or any contraindication to seltorexant or its excipients
The study team makes the final eligibility decision.
Where it is enrolling
- Bryant, Arkansas, United States
- Bellflower, California, United States
- Glendale, California, United States
- Oceanside, California, United States
- Orange, California, United States
- Riverside, California, United States
- Walnut Creek, California, United States
- Doral, Florida, United States
- Hialeah, Florida, United States
- Maitland, Florida, United States
- Miami, Florida, United States
- Tampa, Florida, United States
- West Palm Beach, Florida, United States
- Atlanta, Georgia, United States
- Snellville, Georgia, United States
- Chicago, Illinois, United States
- Baltimore, Maryland, United States
- Boston, Massachusetts, United States
- Watertown, Massachusetts, United States
- Brooklyn, Mississippi, United States
+ 26 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 74 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Bryant, Arkansas, United States; Bellflower, California, United States; Glendale, California, United States; Oceanside, California, United States; Orange, California, United States; Riverside, California, United States and 40 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.